Home Page >> Possible Cases >> Effexor Birth Defects
Effexor linked to Birth Defect PPHN
Effexor, generically called Venlafaxine, is a type of antidepressant known as a serotonin and norepinephrine reuptake inhibitor (SNRI). Several studies conducted over the past few years have linked antidepressants such as Effexor to birth defects in babies whose mothers took prescription antidepressants after the 20th week of pregnancy.
One of the more serious birth defects is Primary Pulmonary Hypertension of the Newborn (PPHN). A study published in the New England Journal of Medicine, and cited by a recent FDA Health Advisory, found that women who took antidepressants similar to Effexor in the second half of pregnancy were six times more likely to give birth to babies who developed PPHN than women who didn't take such medications.
PPH and PPHN
Primary Pulmonary Hypertension (PPH) is a disorder of the lungs in which the arteries are severely restricted. This causes the blood pressure in the pulmonary artery to rise to high levels. As a result, blood flow is restricted and oxygen levels in the blood are decreased.
Infants born with PPHN do not process oxygen in the same way as infants born without it. While the baby is in the womb, blood circulation is controlled by the placenta which supplies oxygen to the baby through the umbilical cord rather than through the lungs. The pulmonary artery sends blood directly back to the heart through the ductus arteriosus.
After birth, circulation switches from the ductus arteriosus, which then permanently closes, to the lungs. However in babies born with PPHN the ductus arteriosus remains open. This prevents the blood flow from entering the lungs, which in turn means that blood returning to the heart is very low in oxygen. Due to the lack of oxygen, the infant's organs become stressed.
Symptoms of PPHN include rapid breathing, rapid heart rate, difficulty breathing, and bluish skin. Heart murmurs and low oxygen levels in the baby's blood are also indicators of PPHN.
Side Effects of PPHN
Even with treatment, infants born with PPHN can experience shock, heart failure, brain hemorrhage, seizures, kidney failure, organ damage, and death. Approximately 20 percent of babies born with PPHN do not survive. Those who do survive may have long-term problems such as breathing difficulties, seizures, developmental disorders, and hearing loss.
In addition to PPHN, the FDA Patient Information Sheet on Effexor notes that babies whose mothers have taken Effexor while pregnant suffer withdrawal symptoms including agitation, insomnia, and difficulty feeding.
Concerns about antidepressants are serious enough that on July 19, 2006 the FDA issued a public health advisory about the medications and asked makers of the drugs to change their prescribing information to include the risk of PPHN.
Effexor is listed as pregnancy Category C by the FDA. This means that animal studies have shown a risk to the fetus but human studies do not indicate whether the risk of birth defects is greater than the risk involved in discontinuing the medication. Effexor can be transferred through breast milk and may harm a nursing baby.
The FDA is currently seeking more information on the risks associated with taking antidepressants while pregnant.
Women who are taking Effexor and are pregnant or thinking about becoming pregnant should consult with their doctor immediately. Women who are breast-feeding and taking Effexor should also discuss their options with their doctors to determine whether or not to continue taking Effexor.
Effexor Birth Defect Complaint
If your child was born with PPHN or later developed PPH, and you took Effexor during pregnancy, a lawyer may be able to help. Please click the link below to submit your Effexor birth defect complaint to a lawyer for a free evaluation.
Posted on Nov-6-06
Updated on Feb-26-07
|
Search 10,000 recent cases and settlements
Lawsuits:
Services:
|